

## **Prospective Assessment of Bone Marrow Involvement with Positron Emission Tomography vs Bone Marrow Biopsy in Patients with Lymphoma**

Suhas Singla, MD, DNB<sup>1</sup>, Sandeep Batra<sup>1</sup>, DNB; Pankaj Dougall<sup>2</sup>, Nitin Dayal<sup>3</sup>, MD; Rahul Naithani<sup>4</sup>, DM, FRCP (Edin)

<sup>1</sup>Department of Medical Oncology, <sup>2</sup>Department of Nuclear Medicine, <sup>3</sup>Department of Hematopathology, <sup>4</sup>Division of Hematology & Bone Marrow Transplantation, Max Superspeciality Hospital, Saket, New Delhi, India.

Word Count-1265, Tables: 3

**Conflict-of-interest statement:** We have no financial relationships to disclose.

### **Corresponding Author**

Dr. Rahul Naithani, MD, DM, FRCP (Edin)

Hematology & Bone Marrow Transplantation

Max Superspeciality Hospital, Delhi, India-110017

Email: [dr\\_rahul6@hotmail.com](mailto:dr_rahul6@hotmail.com),

Fax: +91 11 2223 5563

## Abstract

**Background:** Bone marrow involvement (BM involvement) in lymphoma is a known adverse prognostic factor. Bone marrow biopsy (BMB) is the gold standard for detection of bone marrow involvement but is invasive modality. Positron Emission Tomography with Computed Tomography (PET-CT) scan has the ability to assess bone marrow involvement. We aimed to assess the concordance of PET-CT for BM involvement with BMB.

**Methods:** 75 consecutive newly diagnosed cases of lymphoma were enrolled and were assessed for BM involvement with PET-CT and BMB.

## Results

Of 75 patients, eighteen patients (24%) had BM involvement, with 19% (n=14) detected with BMB, and 13 (17%) with FDG 18 PET CT. There was a concordance rate of 88% amongst PET-CT and BMB. It was 92% in Hodgkin's lymphoma (HL), 71.4% in non-Hodgkin's lymphoma (NHL), and 91% and 70% in high-grade (HG) and low-grade (LG) NHL, respectively. Sensitivity, specificity, PPV, NPV, and accuracy of PET-CT for study population were 69.23%, 93.44%, 69.23%, 93.44%, and 89.19 % respectively. In patients with NHL sensitivity, specificity, NPV, PPV, and accuracy of PET-CT were 54.55%, 94.23%, 66.67%, 90.74%, and 87.30%, respectively; whereas in HL group these were 100%, 88.89% ,75%, 100%, and 91.67%, respectively.

## Conclusions

PET-CT has got a high concordance with bone marrow biopsy in detecting bone marrow involvement with high specificity, NPV and accuracy. A high sensitivity, specificity, NPV and accuracy for detecting bone marrow involvement in patients with HL, aggressive B cell NHL, and T cell NHL was observed but the same parameters were not at par in patient with indolent (low-grade) NHL.

## Introduction

Bone marrow involvement varies amongst the various histopathological types of lymphoma and is usually diagnosed with a bone marrow biopsy, an age old gold standard. It is, however, associated with certain disadvantages such as pain, invasiveness, hemorrhagic manifestations, and inability to inform about the marrow as a whole and missing certain focal lesions.<sup>1,2,3</sup> PET-CT, is an imaging modality widely used in staging of lymphoma and can demonstrate BM involvement with high sensitivity and specificity. However, in certain conditions like infection, inflammation, and anemia it can be falsely positive.<sup>4</sup> There are larger prospective and retrospective studies available. However, prospective and even retrospective data from India is scarce.

In this study, we prospectively tried to find the concordance between PET-CT and bone marrow biopsy for BM involvement in patients with lymphoma and its subtypes.

## Patients & Methods

Newly diagnosed patients of lymphoma with age  $\geq 18$  years were enrolled prospectively. Patients with recurrent, relapsed cases of lymphoma, or with any other concurrent malignancy and who were ineligible to undergo PET-CT or bone marrow biopsy were excluded.

Bone marrow biopsy was interpreted by the expert hematopathologist morphologically and with immunohistochemistry. A positive bone marrow involvement result was defined by focally increased FDG uptake or diffusely increased bone marrow uptake with an intensity greater than that of the liver as assessed by the nuclear medicine expert in the bone marrow

## Statistical Analysis

Data were expressed in terms of percentage and means with standard deviation and median with interquartile range. Fisher's and chi-square test, were used for categorical variables; student t test was used for continuous variables. In all analyses,  $P < 0.05$  was considered statistically significant. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy with Clopper–Pearson exact confidence limits were calculated.

## Results

A total 75 patients fulfilling the inclusion and exclusion criteria were enrolled presenting from Sep 2018 to Jan 2020. The baseline clinical characteristics are demonstrated in table I. Diffuse large B cell lymphoma was the most common pathology (52%). Most patients presented with stage IV disease (43%) and had B symptoms (59%).

Eighteen (24%) patients had BM involvement, and there was no statistical difference in the baseline demographic, clinical, hematological, serological, and pathological parameters in patients with and without BM involvement except for difference in Ki-67 (marker of proliferation);  $41.9 \pm 28.1$  vs  $66.3 \pm 24.7\%$  ( $p$ -value-.001).

BMB and PET-CT detected BM involvement in 14 (19%) and 13 (17%), respectively. Considering BMB as gold standard, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET-CT were sensitivity 69.2, 93.4%, 69.2%, 93.4%, and 89.1%, respectively. PET-CT was concordant with bone marrow biopsy in 88% cases and detected 4 (5%) additional patients with BM involvement and missed 5 patients as detected by bone marrow biopsy. However, on independent analysis for subtypes, maximum concordance

(100%) was observed in T cell NHL amongst patients with NHL followed by 92% each in DLBCL and HL. Least concordance was observed in LG-NHL (70%). Statistical analysis for sensitivity, specificity, PPV, NPV and accuracy were as shown in table II where the sensitivity was lowest in HG-NHL (50%) and highest in HL and T cell NHL. Specificity and accuracy were lowest in LG-NHL. 100% NPV was observed in T cell NHL and HL. Impact of various prognostic factors on the concordance, sensitivity, specificity, PPV, NPV, and accuracy of PET-CT is shown in table II.

## Discussion

Determination of the presence of BM involvement is an important factor as its presence upstages the disease, portends more chances of cytopenia with therapy and may yield to poor stem cell yield. Bone marrow is an invasive test and any non-invasive modality which could replace it is desirable. PET-CT has been explored in various retrospective and prospective studies for its potential to detect BM involvement as shown in table III. However, it had not been very well explored in the Indian subcontinent with a few studies available to mention. We assessed the impact of various prognostic factors on the effectivity of PET-CT to determine BM involvement. PET-CT has high concordance of 78-92% with bone marrow biopsy in detecting BM involvement as depicted in table 5. and was well in coherence with our study where we found it to be 88%. Our findings of sensitivity, specificity, PPV, NVP and accuracy were similar to the data from the previous studies. BM involvement varies amongst the various types of lymphoma varying from <1% to >60% in HL and 10% to >90% in NHL.<sup>5</sup> When analyzed for various subtypes, PET-CT had a 92% concordance and 100% sensitivity in patients with HL, a specificity of 88.89% as one patient detected as having BM involvement on PET-CT was considered as false positive for statistical analysis. Previous studies showed similar findings for predictive and accuracy values. PET-CT is known to have a high a sensitivity, specificity, PPV, NPV and accuracy in patients with HL, with a potential to detect additional patients with BM involvement. In our study PET-CT picked-up all the patients with BM involvement and detected 1 additional patient. Adams et al. in a metaanalysis reinforced the same and concluded that BMB can be replaced with PET-CT in a newly diagnosed case of HL.<sup>6</sup> In patients with NHL, PET-CT tends to have a lower sensitivity and specificity than in patients with HL as found by Pakos et al in the landmark metaanalysis.<sup>7</sup> Though, sensitivity was lower in our study too, we found a higher specificity which may be because of higher number of patients with HG-NHL in this subgroup. PET-CT tends to have a higher concordance, sensitivity and accuracy in patients with HG-NHL as was found in another

metanalysis by Chen et al.<sup>8</sup> Further, in patients with T cell NHL, all the statistical values amounted to 100%, signifying a high rate of concordance as had been previously found in few studies analyzing PET-CT in detection of BM involvement T cell NHL patients.<sup>9</sup> PET-CT has got a high NPV in most of the subtypes of lymphoma except LG-NHL, thus can be utilized for avoiding a painful and invasive procedure like BMB in newly diagnosed case of HL and HG-NHL. We tried to look for certain factors which can determine a subset of patients where BMB can be avoided as PET-CT tends to have a high sensitivity and NPV in those patients. On assessing for the effect of ECOG performance status (ECOG-PS) (“0 to 1” vs “2 to 4”), PET-CT had similar concordance and a higher sensitivity, NPV and PPV in ECOG-PS “2 to 4” subgroup. Similarly, in patients with B symptoms and high serum lactate dehydrogenase PET-CT had a higher sensitivity but no gross difference in NPV was found. In patients with HL, prediction rule for BM involvement by Vassilakopoulos et al. can be used to avoid any theoretical risk of missing BM involvement. BM involvement in patients with LG-NHL should always be ruled out with an iliac crest biopsy.<sup>1</sup>

The limitation of our study was that no quantitative measures such as SUV was used and only qualitative assessment PET-CT was done. No PET-CT directed biopsy were performed which may have increased the yield, though most of the sites were not accessible or the patients refused. Sample size was small, but yet adds information regarding the role of PET CT in assessing the bone marrow.

## **Conclusion**

PET-CT has got a high concordance with bone marrow biopsy in detecting bone marrow involvement with high specificity, NPV and accuracy. It has got a high sensitivity, specificity, NPV and accuracy for detecting bone marrow involvement in patients with Hodgkin's lymphoma, aggressive B cell non-Hodgkin's lymphoma, and T cell non-Hodgkin's lymphoma.

**Table I: Demographic profile of study population**

Characteristics	
Age	56.4 ± 17 years
Sex	
Male	50 (67%)
Female	25 (33%)
Subtypes	
Diffuse Large B Cell Lymphoma	39 (52%)
Hodgkin's Lymphoma	12 (16%)
T Cell Lymphoma	9 (12%)
Follicular Lymphoma	7 (10%)
Marginal Zone Lymphoma	3 (4%)
Primary CNS Lymphoma	2 (3%)
Burkitt Lymphoma	1 (1%)
Mantle cell Lymphoma	1 (1%)
Primary mediastinal B Cell Lymphoma	1 (1%)
Stage	
Stage I	15 (20%)
Stage II	9 (12%)
Stage III	19 (25%)
Stage IV	32 (43%)
ECOG performance status	
"0" to "1"	46 (61%)
"2" to "4"	29 (39%)
B symptoms	44 (59%)



**Table II: Concordance rate of BM and PET CT as per lymphoma subtype**

Type		BMB		Total	p-value	Conco	Sensitivity (%)	Specificity	PPV (%)	NPV (%)	Accuracy (%)	
		No	Yes				(CI 95%)	(CI 95%)	(CI 95%)	(CI 95%)	(CI 95%)	
Overall	PET-CT	No	57	5	62	<0.001	88	64.29	93.44	69.23	91.94	88.00
		Yes	4	9				13	35.14- 87.24	84.05- 98.18	44.68-86.24	84.91-95.85
HL	PET-CT	No	8	0	8	0.018	92	100	88.89	75.00	100	91.67
		Yes	1	3				4	(63.06- 100.00)	(51.75-99.72)		(32.10-95.01)
NHL	PET-CT	No	49	5	54	<0.001	93	54.55	94.23	66.67	90.74	87.3
		Yes	3	6				9	(23.38 - 83.25)	(84.05 - 98.79)	(37.04 - 87.18)	(83.64 - 94.95)
LG-NHL	PET-CT	No	4	2	6	0.524	70	60	80	75	66.67	70
		Yes	1	3				4	(14.66- 94.73)	(28.36-99.49)	(31.11- 95.22)	(38.55- 86.44)
HG-NHL	PET-CT	No	45	3	48	0.008	91	50	95.74	60	93.75	90.57
		Yes	2	3				5	(11.81-88.19)	(85.46- 99.48)	(23.70- 87.87)	(87.05-97.10)
DLBCL	PET-CT	No	34	1	35	0.023	92	66.67	94.44	50	97.14	92.31
		Yes	2	2				4	(9.43-99.16)	(81.34-99.32)	(17.27-82.73)	(87.26-99.14)
T NHL	PET-CT	No	7	0	7	0.028	100	100	100	100	100	100
		Yes	0	2				2	(15.8-100)			(59.04-100)

HL-Hodgkin lymphoma; NHL-Non-hodgkin lymphoma; LG-NHL-Low grade Non-hodgkin lymphoma; HG-NHL-High grade Non-hodgkin lymphoma; DLBCL-Diffuse large B cell lymphoma; T-NHL-T cell non-hodgkin lymphoma

**Table III: Summary of prospective studies**

Author	Year	Number of patients	Country of origin	Type of Lymphoma	Concordance	Sensitivity	Specificity	PPV	NPV	Accuracy
<b>Prospective (Indian)</b>										
Current study	2020	75	India	Overall	88	69.2	93.4	69.2	93.4	89.2
				HL (n=12)	92	100	88.9	75	100	91.7
				NHL (n=63)	71.4	54.6	94.2	66.7	90.7	87.3
Mittal et al <sup>10</sup>	2011	97	India	Overall	92	89	93	89	93	NA
				HL (n=20)	90	100	86	71	100	NA
				NHL (n=77)	92	100	94	93	100	NA
<b>Prospective (International)</b>										
Xiao-Xue et al <sup>11</sup>	2020	153	China	Overall	74.5	54.3	80.5	NA	NA	74.5
				HL (n=15)	47	0	46.7	NA	NA	46.7
				B-NHL (n= 59)	88.1	80	90	NA	NA	88.1
				FL (n = 24)	71	37.5	87.5	NA	NA	70.8
				T-NHL (n = 34)	76.5	57.1	81.5	NA	NA	76.5
Voltin et al <sup>12</sup>	2018	832	Germany	HL	87	95	86.5	14.7	99.9	NA
Özpolat et al <sup>13</sup>	2018	38	Turkey	Overall	57	77	51	88	33	NA
				NHL (22)	68	NA	NA	57	95	NA
				HL (16)	37.5	NA	NA	90	100	NA
Alzahrani et al <sup>14</sup>	2016	530	Canada	DLBCL	76	60	79	36	91	NA
Corte´s-Romera et al <sup>15</sup>	2014	147	Spain	DLBCL/ HL	87	95	86	87	54	99
Shih-Feng Cho et al <sup>16</sup>	2015	185	China	Overall	82.1	50	91.6	63.6	86.2	NA
				aB-NHL	88.1	70	92.1	66.7	93.2	88
				HL	93.8	NA	NA	NA	100	NA
				FL & MZL	65-67	27.8	89.7	62.5	66.7	65.9
				T-cell	76.9	50	88.9	66.7	80	76.9
El-Galaly et al <sup>17</sup>	2012	454	Germany	HL	85	85	86	28	99	86
Ngeow et al <sup>18</sup>	2009	122	Singapore	B-NHL (n=63)	90	41	95	91	58	NA
				B-NHL (n=21)	67	57	95	57	95	NA
				T cell NHL (n=17)	100	100	100	100	100	NA
				HL (n=21)	90	100	90	33	100	NA
Carr et al <sup>19</sup>	1998	50	UK	NHL (38) /HL (12)	78	NA	NA	NA	NA	NA
Moog et al <sup>20</sup>	1998	78	Germany	NHL (39)/HL (39)	82.1	81	100	NA	NA	NA
<b>Retrospective (Indian)</b>										
Agrawal et al <sup>21</sup>	2013	38	India	HL (paediatric)	81.6	87.5	100	100	96	NA

## References

---

- <sup>1</sup> Vassilakopoulos TP, Angelopoulou MK, Constantinou N, Karmiris T, Repoussis P, Roussou P, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. *Blood*. 2005 Mar 1;105(5):1875–80.
- <sup>2</sup> Nakajima R, Moskowitz AJ, Michaud L, Mauguen A, Batlevi CL, Dogan A, Schöder H. Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. *Blood Adv*. 2020 Apr 28;4(8):1812-1823.
- <sup>3</sup> Chen-Liang T-H, Martin-Santos T, Jerez A, Senent L, Orero MT, Remigia MJ, et al. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high-grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. accuracy in a multicenter series of 372 patients. *Am J Hematol*. 90(8):686–90.
- <sup>4</sup> Jha SK, Borah P, Jeyaraman P, Jain A, Kumar D, Bal J, Naithani R. All That Lights-Up is not Lymphoma. *Indian J Hematol Blood Transfus*. 2020 Jan;36(1):213-214.
- <sup>5</sup> Jitani AK, Dutta S, Mandal PK, De R, Jajodia E, Baul S, Chakrabarti P, Dolai TK. Utility of <sup>18</sup>F-fluorodeoxyglucose PET-CT scan in detecting bone marrow involvement in lymphoma. *Indian J Med Res*. 2021 May;154(5):691-698.
- <sup>6</sup> Adams HJA, Kwee TC, de Keizer B, Fijnheer R, de Klerk JMH, Littooi AS, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? *Ann Oncol Off J Eur Soc Med Oncol*. 2014 May;25(5):921–7.
- <sup>7</sup> Pakos EE, Fotopoulos AD, Ioannidis JPA. <sup>18</sup>F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. *J Nucl Med Off Publ Soc Nucl Med*. 2005 Jun;46(6):958–63.
- <sup>8</sup> Chen Y-K, Yeh C-L, Tsui C-C, Liang J-A, Chen J-H, Kao C-H. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. *Clin Nucl Med*. 2011 Jul;36(7):553–9.
- <sup>9</sup> McKenna RW, Hernandez JA. Bone marrow in malignant lymphoma. *Hematol Oncol Clin North Am*. 1988 Dec;2(4):617–35.
- <sup>10</sup> Mittal BR, Manohar K, Malhotra P, Das R, Kashyap R, Bhattacharya A, Varma N, Varma S. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging? *Leuk Lymphoma*. 2011 Nov;52(11):2111-6.
- <sup>11</sup> Xiao-Xue W, Xinyue H, Lijun Z. Whole body FDG-PET/CT for the assessment of bone marrow infiltration in patients with newly diagnosed lymphoma. *Med Clínica*. 2020 Jan 24;154(2):61–5.
- <sup>12</sup> Voltin C-A, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, et al. Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. *Ann Oncol Off J Eur Soc Med Oncol*. 2018 01;29(9):1926–31.

- 
- <sup>13</sup> Özpolat HT, Yılmaz E, Goksoy HS, Özpolat S, Dogan Ö, Unal SN, et al. Detection of bone marrow involvement with FDG PET/CT in patients with newly diagnosed lymphoma. *Blood Res.* 2018 Dec;53(4):281–7.
- <sup>14</sup> Alzahrani M, El-Galaly TC, Hutchings M, Hansen JW, Loft A, Johnsen HE, et al. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study†. *Ann Oncol.* 2016 Jun 1;27(6):1095–9.
- <sup>15</sup> Cortés-Romera M, Sabaté-Llobera A, Mercadal-Vilchez S, Climent-Esteller F, Serrano-Maestro A, Gámez-Cenzano C, et al. Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy. *Clin Nucl Med.* 2014 Jan;39(1):e46-52.
- <sup>16</sup> Cho SF, Chang CC, Liu YC, Chang CS, Hsiao HH, Liu TC, Huang CT, Lin SF. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma. *Kaohsiung J Med Sci.* 2015 Mar;31(3):130-7.
- <sup>17</sup> El-Galaly TC, d'Amore F, Mylam KJ, de Nully Brown P, Bøgsted M, Bukh A, et al. Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients with Hodgkin Lymphoma. *J Clin Oncol.* 2012 Dec 20;30(36):4508–14.
- <sup>18</sup> Ngeow JYY, Quek RHH, Ng DCE, Hee SW, Tao M, Lim LC, et al. High SUV uptake on FDG–PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG–PET/CT staging in lymphoma. *Ann Oncol.* 2009 Sep 1;20(9):1543–7.
- <sup>19</sup> Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. *Blood.* 1998 May 1;91(9):3340–6.
- <sup>20</sup> Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. *J Clin Oncol Off J Am Soc Clin Oncol.* 1998 Feb;16(2):603–9.
- <sup>21</sup> Agrawal K, Mittal BR, Bansal D, Varma N, Srinivasan R, Trehan A, Manohar K, Kashyap R, Bhattacharya A, Marwaha RK. Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's lymphoma. *Ann Nucl Med.* 2013 Feb;27(2):146-51.